424870 — ImmuneOncia therapeutics Income Statement
0.000.00%
Last trade - 00:00- KR₩727bn
- KR₩703bn
- KR₩111m
Annual income statement for ImmuneOncia therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 110 | 655 | 111 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Total Operating Expenses | 11,907 | 13,253 | 28,116 |
| Operating Profit | -11,797 | -12,599 | -28,005 |
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | 8,864 | -5,687 | -27,363 |
| Provision for Income Taxes | |||
| Net Income After Taxes | 8,864 | -5,687 | -27,363 |
| Net Income Before Extraordinary Items | |||
| Net Income | 8,864 | -5,687 | -27,363 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | 8,864 | -5,687 | -27,363 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | 121 | -77.9 | -390 |